Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Sangamo Therapeutics, Inc. has been rated as a "Moderate Buy" by six brokerages, with an average twelve-month target price of $4.50.
• The company recently reported a quarterly EPS of (-0.08), missing analysts' expectations and generating revenue of $18.31 million, significantly below the anticipated $31.68 million.
• Shares of Sangamo Therapeutics saw a 17.5% increase recently, with the stock currently trading at $0.52.

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $4.50.

SGMO has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, May 30th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, June 24th. Finally, Barclays decreased their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th.

Sangamo Therapeutics Trading Up 17.5%

Shares of SGMO stock opened at $0.52 on Wednesday. The firm has a market capitalization of $120.67 million, a PE ratio of -1.78 and a beta of 1.18. The firm has a fifty day simple moving average of $0.52 and a two-hundred day simple moving average of $0.72. Sangamo Therapeutics has a 12 month low of $0.41 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. On average, equities analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of hedge funds have recently bought and sold shares of SGMO. Point72 Asset Management L.P. purchased a new position in Sangamo Therapeutics during the 4th quarter worth $2,316,000. Schonfeld Strategic Advisors LLC purchased a new position in Sangamo Therapeutics during the 4th quarter worth $1,744,000. GSA Capital Partners LLP boosted its holdings in Sangamo Therapeutics by 2,962.2% during the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company's stock worth $634,000 after acquiring an additional 934,649 shares during the last quarter. Acuta Capital Partners LLC purchased a new position in Sangamo Therapeutics during the 4th quarter worth $755,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Sangamo Therapeutics in the 4th quarter worth about $722,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.